{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:49:22Z","timestamp":1792090162224,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The incidence of transfusion-transmitted cytomegalovirus (TT-CMV) after hematopoietic stem cell transplantation (HSCT) in the era of universal leukoreduction remains unclear. This study evaluated temporal changes in TT-CMV and clinically significant CMV infection (csCMVi) in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from 5,016\u00a0CMV-seronegative HSCT recipients registered between 1999 and 2022 were retrospectively analyzed. TT-CMV was defined as CMV antigenemia and\/or CMV disease, and csCMVi as the initiation of pre-emptive therapy or CMV disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Random donor (RD) blood products were independently associated with TT-CMV (odds ratio 2.35, 95% confidence interval 1.75\u20133.15,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and csCMVi (subdistribution hazard ratio 2.22, 95% CI 1.67\u20132.96,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among allogeneic HSCT recipients receiving RD blood products, TT-CMV decreased from 25.7% in 2007\u20132020 to 12.7% in 2021\u20132022, while the 100-day cumulative incidence of csCMVi decreased from 24.7% to 8.3% over the same periods. During 2021\u20132022, differences between RD and CMV-seronegative donor blood products were not statistically significant. CMV disease incidence did not differ between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TT-CMV and csCMVi decreased substantially over time. Although RD blood products remained associated with higher overall risk, the additional benefit of CMV-seronegative blood products may be limited under contemporary transfusion practices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12185-026-04295-y","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:00:45Z","timestamp":1792087245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends in transfusion-transmitted cytomegalovirus infection among cytomegalovirus-seronegative HSCT recipients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-7857","authenticated-orcid":false,"given":"Kimikazu","family":"Yakushijin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Transplant Complications Working Group. of the Japanese Society for Transplantation and Cellular Therapy (JSTCT)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"4295_CR1","doi-asserted-by":"publisher","first-page":"e70142","DOI":"10.1002\/rmv.70142","volume":"36","author":"D Kaplan","year":"2026","unstructured":"Kaplan D, Blyth E, Sutrave G, Yong MK, Gottlieb DJ, Abendroth A, et al. Human cytomegalovirus infection in haematopoietic stem cell transplant recipients and CAR T cell recipients - part 1: risk factors, clinical impact and immune response. Rev Med Virol. 2026;36:e70142.","journal-title":"Rev Med Virol"},{"key":"4295_CR2","first-page":"227","volume":"7","author":"WJ Miller","year":"1991","unstructured":"Miller WJ, McCullough J, Balfour HH Jr, Haake RJ, Ramsay NK, Goldman A, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991;7:227\u201334.","journal-title":"Bone Marrow Transplant"},{"key":"4295_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/tme.12437","volume":"27","author":"M Ziemann","year":"2017","unstructured":"Ziemann M, Thiele T. Transfusion-transmitted CMV infection - current knowledge and future perspectives. Transfus Med. 2017;27:238\u201348.","journal-title":"Transfus Med"},{"key":"4295_CR4","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1128\/jvi.68.10.6243-6253.1994","volume":"68","author":"CA Stoddart","year":"1994","unstructured":"Stoddart CA, Cardin RD, Boname JM, Manning WC, Abenes GB, Mocarski ES. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J Virol. 1994;68:6243\u201353.","journal-title":"J Virol"},{"key":"4295_CR5","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","volume":"86","author":"RA Bowden","year":"1995","unstructured":"Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598\u2013603.","journal-title":"Blood"},{"key":"4295_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.46989\/001c.94135","volume":"6","author":"BD Adkins","year":"2024","unstructured":"Adkins BD, Jacobs JW, Booth GS, Savani BN, Stephens LD. Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review. Clin Hematol Int. 2024;6:128\u201340.","journal-title":"Clin Hematol Int"},{"key":"4295_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/vox.12373","volume":"110","author":"R Yanagisawa","year":"2016","unstructured":"Yanagisawa R, Shimodaira S, Sakashita K, Hidaka Y, Kojima S, Nishijima F, et al. Factors related to allergic transfusion reactions and febrile non-haemolytic transfusion reactions in children. Vox Sang. 2016;110:376\u201384.","journal-title":"Vox Sang"},{"key":"4295_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/jcm.19.2.147-152.1984","volume":"19","author":"JA Brandt","year":"1984","unstructured":"Brandt JA, Kettering JD, Lewis JE. Immunity to human cytomegalovirus measured and compared by complement fixation, indirect fluorescent-antibody, indirect hemagglutination, and enzyme-linked immunosorbent assays. J Clin Microbiol. 1984;19:147\u201352.","journal-title":"J Clin Microbiol"},{"key":"4295_CR9","unstructured":"Takenaka K, Kanda Y, Mori T, Mori Y, Yokoyama T, Kimura S, Kato M. \u201cCytomegalovirus infection guideline\u201d (5th ed). JSTCT guideline (monograph).2024; 5:97"},{"key":"4295_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"4295_CR11","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","volume":"25","author":"P Ljungman","year":"2025","unstructured":"Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025;25:e451\u201362.","journal-title":"Lancet Infect Dis"},{"key":"4295_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tmrv.2005.02.002","volume":"19","author":"EC Vamvakas","year":"2005","unstructured":"Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19:181\u201399.","journal-title":"Transfus Med Rev"},{"key":"4295_CR13","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1537-2995.2011.03203.x","volume":"51","author":"T Thiele","year":"2011","unstructured":"Thiele T, Kruger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion. 2011;51:2620\u20136.","journal-title":"Transfusion"},{"key":"4295_CR14","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.bbmt.2013.09.013","volume":"19","author":"N Kekre","year":"2013","unstructured":"Kekre N, Tokessy M, Mallick R, McDiarmid S, Huebsch L, Bredeson C, et al. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant. 2013;19:1719\u201324.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4295_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/tme.12219","volume":"25","author":"S Hall","year":"2015","unstructured":"Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, et al. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience. Transfus Med. 2015;25:418\u201323.","journal-title":"Transfus Med"},{"key":"4295_CR16","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/j.1537-2995.2012.03739.x","volume":"52","author":"T Nash","year":"2012","unstructured":"Nash T, Hoffmann S, Butch S, Davenport R, Cooling L. Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion. 2012;52:2270\u20132.","journal-title":"Transfusion"},{"key":"4295_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/trf.13478","volume":"56","author":"M Mainou","year":"2016","unstructured":"Mainou M, Alahdab F, Tobian AA, Asi N, Mohammed K, Murad MH, et al. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. Transfusion. 2016;56:1569\u201380.","journal-title":"Transfusion"},{"key":"4295_CR18","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1111\/trf.15456","volume":"59","author":"T Shigemura","year":"2019","unstructured":"Shigemura T, Yanagisawa R, Komori K, Morita D, Kurata T, Tanaka M, et al. Prevention of transfusion-transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation. Transfusion. 2019;59:3065\u201370.","journal-title":"Transfusion"},{"key":"4295_CR19","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1111\/trf.12390","volume":"53","author":"Y Furui","year":"2013","unstructured":"Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion. 2013;53:2190\u20137.","journal-title":"Transfusion"},{"key":"4295_CR20","first-page":"446-453","volume":"18","author":"S Voruz","year":"2020","unstructured":"Voruz S, Gowland P, Eyer C, Widmer N, Abonnenc M, Prudent M, et al. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing A study on the safety of labile blood components in Switzerland. Blood Transfus. 2020;18:446\u2013453.","journal-title":"Blood Transfus"},{"key":"4295_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/vox.70219","volume":"121","author":"PJ Crispin","year":"2026","unstructured":"Crispin PJ, Edwards D, Beattie K, Brown K, Clarke L, King F, et al. Serological screening for cytomegalovirus in a leucodepleted blood supply: a systematic review. Vox Sang. 2026;121:722\u201331.","journal-title":"Vox Sang"},{"key":"4295_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/00007890-200202270-00015","volume":"73","author":"Y Kanda","year":"2002","unstructured":"Kanda Y, Mineishi S, Saito T, Saito A, Ohnishi M, Niiya H, et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplant. 2002;73:568\u201372.","journal-title":"Transplant"},{"key":"4295_CR23","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260\u201372.","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04295-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:00:46Z","timestamp":1792087246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04295-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":23,"alternative-id":["4295"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04295-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.Y. has received research grants and honoraria from MSD K.K. and was one of the lead reviewers of International Journal of Hematology. M.O. received lecture fees from MSD K.K. and the Japanese Red Cross Society. Min.Ku. and H.N. have received honoraria from MSD K.K. F.I. is an employee of Japanese Red Cross Society. Yoshinobu Kanda and Mineo Kurokawa are associate editors of International Journal of Hematology. The other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}